

IPAR



Publicly Available Assessment Report for a Veterinary Medicinal Product

Buprenodale Multidose, 0.3 mg/ml solution for
injection for dogs, cats and horses

PRODUCT SUMMARY

EU Procedure Number	IE/V/0532/001 (formerly UK/V/0475/001)
Name, Strength, Pharmaceutical Form	Buprenodale Multidose, 0.3 mg/ml solution for injection for dogs, cats and horses
Active Substances(s)	Buprenorphine hydrochloride
Applicant	Dechra Regulatory B.V., Handelsweg 25, 5531 AE Bladel, Netherlands
Legal Basis of Application	Generic application (Article 13(1) of Directive No 2001/82/EC)
Target Species	Cats,Dogs,Non food-producing horses
Indication For Use	Post-operative analgesia in the dog and cat. Post-operative analgesia, in combination with sedation, in the horse. Potentiation of the sedative effects of centrally acting agents in the dog and horse.
ATC Code	QN02AE01
Date of completion of the original decentralised procedure	31 July 2013 (UK) 04 October 2013 (IE)
Date product first authorised in the Reference Member State (MRP only)	N/A
Concerned Member States for original procedure	Austria, Belgium, Czech Republic, Denmark, France, Germany, Hungary, Ireland (now RMS), Italy, Luxembourg, Netherlands, Portugal, Slovakia, Spain, Sweden UK added via RMS change

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the

scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

Buprenodale Multidose 0.3 mg/ml Solution for Injection has been developed as a generic of Vetergesic Multidose 0.3 mg/ml Solution for Injection. Buprenodale Multidose contains 0.3 mg/ml buprenorphine and is indicated for post-operative analgesia in the dog, cat and horse, as well as to potentiate the effect of sedation in the dog and horse.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains the active substance buprenorphine hydrochloride and the excipients chlorocresol, glucose monohydrate, sodium hydroxide, hydrochloric acid and water for injection.

The container/closure system consists of a clear Type I glass vial closed with a bromobutyl rubber stopper and aluminium seal, containing 10 ml of solution and packaged in a cardboard carton. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation is justified. The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The product is manufactured by dissolving the excipients in the water injection before dissolving the

active substance in the solution. The pH is adjusted before the solution is filtered and the glass vials are filled, stoppered and sealed. Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is buprenorphine hydrochloride, an established active substance described in the European Pharmacopoeia. A certificate of suitability has been provided for the manufacturer of the active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

All excipients are described in the European Pharmacopoeia and comply with the requirements of the relevant monographs. Certificates of analysis were provided for all excipients.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control on intermediate products

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Test on the finished product include those for identification and assay of the active substance, identification of the excipients, pH, appearance and sterility.

Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions. The retest period for the active substance is 4 years.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions. Data were provided for batches stored at 25°C/60%RH and 40°C/75%RH. The shelf life for the finished product has been established as 2 years.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

- Shelf life of the finished product as packaged for sale: 2 years.
- Shelf life after first opening the immediate packaging: 28 days.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product can be assumed because of the nature of the product, results of pharmacological studies are not required.

Toxicological Studies

As this is a generic application according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product can be assumed because of the nature of the product, results of toxicological studies are not required.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline, identifying the most likely route of exposure as accidental self-injection and also stating dermal or ocular exposure were possible but unlikely. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product:

- As buprenorphine has opioid-like activity, care should be taken to avoid accidental self-injection. In case of accidental self-injection or ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
- Following eye contamination or skin contact, wash thoroughly with cold running water. Seek medical advice if irritation persists.

Ecotoxicity

The applicant provided a Phase I environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required. The assessment concluded that the product is for use in dogs, cats and individual horses, it is therefore not expected to pose a risk to the environment.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

The product is intended for use in dogs, cats and horses. No MRLs are established for buprenorphine and no residues studies were submitted as the product is contraindicated in horses intended for human consumption. Adequate warnings are included in the SPC and product literature:

- The product is not authorised for use in horses intended for human consumption.

IV. CLINICAL ASSESSMENT

IV.A Pre-Clinical Studies

Pharmacology

As this is a generic application according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product can be assumed because of the nature of the product, results of pharmacological studies are not required.

Tolerance in the Target Species of Animals

As this is a generic application according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product can be assumed because of the nature of the product, results of target animal tolerance studies are not required.

IV.B Clinical Studies

As this is a generic application according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product can be assumed because of the nature of the product, results of clinical studies are not required.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.